Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
| ▸ | PEPD | P12955 | 1/20 | 0.31 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.30 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21515921 | 1.00 | PIN1 (0.33) | PIN1DPP4DPP8DPP9CHRM2 | |
| SCHEMBL8915827 | 1.00 | PIN1 (0.33) | PIN1DPP4DPP8DPP9CHRM2 | |
| SCHEMBL13165479 | 1.00 | PIN1 (0.33) | PIN1DPP4DPP8DPP9CHRM2 | |
| SCHEMBL17995266 | 0.83 | ATM (0.38) | PIN1DPP4DPP8DPP9PEPD | |
| SCHEMBL19540491 | 0.83 | ATM (0.38) | PIN1DPP4DPP8DPP9PEPD | |
| SCHEMBL22360773 | 0.83 | ATM (0.38) | PIN1DPP4DPP8DPP9PEPD | |
| SCHEMBL755185 | 0.83 | ATM (0.38) | PIN1DPP4DPP8DPP9PEPD | |
| SCHEMBL10140519 | 0.81 | DPP4 (0.31) | PIN1DPP4DPP8DPP9PEPD | |
| SCHEMBL12861032 | 0.81 | PIN1 (0.41) | PIN1DPP4DPP8DPP9PEPD | |
| SCHEMBL12860983 | 0.81 | PIN1 (0.41) | PIN1DPP4DPP8DPP9PEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | NOSOPHARM (FR) | 2017-10-19 | — | — | US | disclosed |
| EP-2400846-B1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARM INC (US) | 2016-10-05 | — | — | EP | disclosed |
| WO-2016046409-A1 | NOVEL PEPTIDE DERIVATIVES AND USES THEREOF | NOSOPHARM (FR) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | VIP, IAPP, NGLY1 | PIN1 462/4885DPP4 18/4885DPP8 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.